Marinus Pharmaceuticals (MRNS) Competitors $0.31 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MRNS vs. RAPT, BYSI, CLRB, ALVR, ALGS, CELU, PROC, ALXO, IMRX, and MGXShould you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include RAPT Therapeutics (RAPT), BeyondSpring (BYSI), Cellectar Biosciences (CLRB), AlloVir (ALVR), Aligos Therapeutics (ALGS), Celularity (CELU), Procaps Group (PROC), ALX Oncology (ALXO), Immuneering (IMRX), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. Marinus Pharmaceuticals vs. RAPT Therapeutics BeyondSpring Cellectar Biosciences AlloVir Aligos Therapeutics Celularity Procaps Group ALX Oncology Immuneering Metagenomi Marinus Pharmaceuticals (NASDAQ:MRNS) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment. Which has better earnings and valuation, MRNS or RAPT? RAPT Therapeutics has lower revenue, but higher earnings than Marinus Pharmaceuticals. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarinus Pharmaceuticals$30.99M0.55-$141.40M-$2.47-0.13RAPT Therapeutics$1.53M24.45-$116.80M-$2.77-0.39 Is MRNS or RAPT more profitable? RAPT Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. RAPT Therapeutics' return on equity of -89.10% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marinus Pharmaceuticals-446.48% -7,831.35% -120.74% RAPT Therapeutics N/A -89.10%-76.13% Does the MarketBeat Community favor MRNS or RAPT? Marinus Pharmaceuticals received 348 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 67.96% of users gave Marinus Pharmaceuticals an outperform vote while only 63.12% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformMarinus PharmaceuticalsOutperform Votes43767.96% Underperform Votes20632.04% RAPT TherapeuticsOutperform Votes8963.12% Underperform Votes5236.88% Do institutionals & insiders have more ownership in MRNS or RAPT? 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are held by institutional investors. 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to MRNS or RAPT? In the previous week, Marinus Pharmaceuticals and Marinus Pharmaceuticals both had 12 articles in the media. RAPT Therapeutics' average media sentiment score of 0.52 beat Marinus Pharmaceuticals' score of 0.34 indicating that RAPT Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marinus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral RAPT Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MRNS or RAPT? Marinus Pharmaceuticals presently has a consensus target price of $4.79, indicating a potential upside of 1,448.77%. RAPT Therapeutics has a consensus target price of $9.50, indicating a potential upside of 787.85%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Marinus Pharmaceuticals is more favorable than RAPT Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36RAPT Therapeutics 1 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.08 Which has more volatility and risk, MRNS or RAPT? Marinus Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. SummaryMarinus Pharmaceuticals beats RAPT Therapeutics on 9 of the 17 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNS vs. The Competition Export to ExcelMetricMarinus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.05M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E Ratio-0.1310.02126.5217.52Price / Sales0.55318.981,203.9085.12Price / CashN/A22.1633.3732.51Price / Book1.005.464.684.68Net Income-$141.40M$152.97M$118.36M$225.62M7 Day Performance2.22%-4.33%-2.46%-2.04%1 Month Performance-83.30%-8.65%-4.06%0.03%1 Year Performance-94.96%28.53%29.55%24.47% Marinus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNSMarinus Pharmaceuticals4.5957 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$16.97M$30.99M-0.13110Analyst ForecastAnalyst RevisionRAPTRAPT Therapeutics4.5981 of 5 stars$1.07flat$9.50+787.9%-92.3%$37.40M$1.53M0.0080BYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$66.74M$1.75M0.0080CLRBCellectar Biosciences2.4942 of 5 stars$1.56-3.1%$20.00+1,182.1%-27.8%$66.44MN/A0.0010Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageALVRAlloVir2.6268 of 5 stars$0.57+1.8%N/A-65.2%$65.87MN/A-0.65110Positive NewsALGSAligos Therapeutics4.3215 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$65.30M$6.00M-1.3990High Trading VolumeCELUCelularity0.5401 of 5 stars$2.94+0.7%N/A+42.7%$64.64M$42.69M0.00220News CoveragePROCProcaps Group1.4951 of 5 stars$0.57+7.5%N/A-77.2%$64.48M$414.10M0.995,500High Trading VolumeALXOALX Oncology3.3343 of 5 stars$1.21-1.6%$12.50+933.1%-87.7%$63.82MN/A-0.4140IMRXImmuneering3.1656 of 5 stars$2.04flat$12.80+527.5%-63.4%$63.34M$320,000.00-1.0460Analyst ForecastMGXMetagenomi2.8114 of 5 stars$1.65-2.4%$15.50+839.4%N/A$63.25M$44.76M0.00236Analyst Forecast Related Companies and Tools Related Companies RAPT Therapeutics Competitors BeyondSpring Competitors Cellectar Biosciences Competitors AlloVir Competitors Aligos Therapeutics Competitors Celularity Competitors Procaps Group Competitors ALX Oncology Competitors Immuneering Competitors Metagenomi Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRNS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRNS Stock Alerts